WO2014124258A3 - Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués - Google Patents

Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués Download PDF

Info

Publication number
WO2014124258A3
WO2014124258A3 PCT/US2014/015302 US2014015302W WO2014124258A3 WO 2014124258 A3 WO2014124258 A3 WO 2014124258A3 US 2014015302 W US2014015302 W US 2014015302W WO 2014124258 A3 WO2014124258 A3 WO 2014124258A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific sites
modifying antibodies
antibody fragments
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/015302
Other languages
English (en)
Other versions
WO2014124258A2 (fr
Inventor
Bernhard Hubert GEIERSTANGER
Weijia Ou
Tetsuo Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of WO2014124258A2 publication Critical patent/WO2014124258A2/fr
Publication of WO2014124258A3 publication Critical patent/WO2014124258A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des sites spécifiques de modification d'anticorps ou de fragments d'anticorps par le remplacement d'au moins un acide aminé dans la région constante d'un anticorps ou d'un fragment d'anticorps parental par un acide aminé codé par TAG tel que Pcl, qui peut être utilisé au niveau d'un site de fixation d'une charge ou d'une combinaison lieur-charge. L'invention comprend des anticorps ou des fragments d'anticorps modifiés, divers conjugués formés à partir de ceux-ci et des utilisations des anticorps ou des fragments d'anticorps modifiés et de leurs conjugués.
PCT/US2014/015302 2013-02-08 2014-02-07 Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués Ceased WO2014124258A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361762636P 2013-02-08 2013-02-08
US61/762,636 2013-02-08

Publications (2)

Publication Number Publication Date
WO2014124258A2 WO2014124258A2 (fr) 2014-08-14
WO2014124258A3 true WO2014124258A3 (fr) 2014-11-20

Family

ID=50179937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/015302 Ceased WO2014124258A2 (fr) 2013-02-08 2014-02-07 Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués

Country Status (1)

Country Link
WO (1) WO2014124258A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900755C (fr) 2013-02-08 2021-07-20 Irm Llc Sites specifiques de modification d'anticorps pour fabriquer des immunoconjugues
EP3878861B1 (fr) * 2015-02-16 2025-05-07 Lonza Ltd. Anticorps mutés cl et/ou ch1 pour la conjugation médicamenteuse
WO2016203432A1 (fr) 2015-06-17 2016-12-22 Novartis Ag Conjugués anticorps-médicament
JP6967221B2 (ja) * 2015-08-19 2021-11-17 国立研究開発法人理化学研究所 非天然アミノ酸導入抗体
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JP7275049B2 (ja) 2017-12-27 2023-05-17 協和キリン株式会社 Ｉｌ－２改変体
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
PH12021551479A1 (en) 2018-12-21 2022-07-18 Novartis Ag Antibodies to pmel17 and conjugates thereof
CA3138058A1 (fr) 2019-05-20 2020-11-26 Matthew T. Burger Conjugues anticorps-medicament inhibiteurs de mcl-1 et procedes d'utilisation
WO2021168274A1 (fr) * 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Conjugués d'anticorps de nectine-4 et leurs utilisations
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2022115451A1 (fr) 2020-11-24 2022-06-02 Novartis Ag Conjugués anticorps-médicament inhibiteurs de mcl-1 et procédés d'utilisation
WO2022221720A1 (fr) 2021-04-16 2022-10-20 Novartis Ag Conjugués anticorps-médicament et leurs procédés de fabrication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184514A1 (fr) * 2012-06-04 2013-12-12 Irm Llc Méthodes de marquage spécifiques à un site et molécules ainsi produites
WO2013185115A1 (fr) * 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (fr) 1989-11-06 1991-05-16 Enzytech, Inc. Microspheres de proteines et leurs procedes d'utilisation
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
CA2076465C (fr) 1992-03-25 2002-11-26 Ravi V. J. Chari Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065
CA2118508A1 (fr) 1992-04-24 1993-11-11 Elizabeth S. Ward Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (fr) 1997-05-21 1998-11-26 Biovation Limited Procede de production de proteines non immunogenes
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CA2336139C (fr) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
US8785151B2 (en) 2008-10-24 2014-07-22 Bernhard Geierstanger Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
US11605302B2 (en) 2020-11-10 2023-03-14 Rockwell Collins, Inc. Time-critical obstacle avoidance path planning in uncertain environments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184514A1 (fr) * 2012-06-04 2013-12-12 Irm Llc Méthodes de marquage spécifiques à un site et molécules ainsi produites
WO2013185115A1 (fr) * 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "www.bioinf.org.uk : Dr. Andrew C.R. Martin's Group at UCL", 25 February 2014 (2014-02-25), XP055122195, Retrieved from the Internet <URL:http://www.bioinf.org.uk/abs/> [retrieved on 20140606] *
DOWDY JACKSON ET AL: "In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates", PLOS ONE, vol. 9, no. 1, 14 January 2014 (2014-01-14), pages e83865, XP055101735, DOI: 10.1371/journal.pone.0083865 *
F. TIAN ET AL: "A general approach to site-specific antibody drug conjugates", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 5, 17 January 2014 (2014-01-17), pages 1766 - 1771, XP055101730, ISSN: 0027-8424, DOI: 10.1073/pnas.1321237111 *
F. TIAN ET AL: "A general approach to site-specific antibody drug conjugates", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 5, 17 January 2014 (2014-01-17), pages 1766 - 1771, XP055122307, ISSN: 0027-8424, DOI: 10.1073/pnas.1321237111 *
GERALD M EDELMAN ET AL, IOCHEMISTRY, 1 June 1969 (1969-06-01), pages 78 - 85, XP055122293 *
HSIEN-PO CHIU ET AL: "Simultaneous Purification and Site-Specific Modification of Pyrroline-Carboxy-Lysine Proteins", CHEMBIOCHEM, vol. 13, no. 3, 5 January 2012 (2012-01-05), pages 364 - 366, XP055122231, ISSN: 1439-4227, DOI: 10.1002/cbic.201100684 *
J. Y. AXUP ET AL: "Synthesis of site-specific antibody-drug conjugates using unnatural amino acids", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 40, 2 October 2012 (2012-10-02), pages 16101 - 16106, XP055076259, ISSN: 0027-8424, DOI: 10.1073/pnas.1211023109 *
MARSHA A. GASTON ET AL: "The complete biosynthesis of the genetically encoded amino acid pyrrolysine from lysine", NATURE, vol. 471, no. 7340, 31 March 2011 (2011-03-31), pages 647 - 650, XP055081693, ISSN: 0028-0836, DOI: 10.1038/nature09918 *
W. OU ET AL: "Site-specific protein modifications through pyrroline-carboxy-lysine residues", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 26, 28 June 2011 (2011-06-28), pages 10437 - 10442, XP055122289, ISSN: 0027-8424, DOI: 10.1073/pnas.1105197108 *

Also Published As

Publication number Publication date
WO2014124258A2 (fr) 2014-08-14

Similar Documents

Publication Publication Date Title
WO2014124316A3 (fr) Sites spécifiques de modification d&#39;anticorps pour fabriquer des immunoconjugués
WO2015138615A3 (fr) Sites spécifiques utilisables pour la modification d&#39;anticorps en vue de l&#39;obtention d&#39;immunoconjugués
WO2014160160A3 (fr) Conjugués anticorps-médicaments
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
HK1207654A1 (en) Modified antibody regions and uses thereof
HK1218549A1 (zh) 新型抗体框架
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
WO2014197849A3 (fr) Anticorps anti-c10orf54 et leurs utilisations
WO2015091853A3 (fr) Anticorps
WO2014191113A8 (fr) Nouveaux anticorps
WO2015013389A3 (fr) Anticorps monoclonaux anti-galectine-1 (gal1) et leurs fragments pour neutraliser gal1
WO2014163714A3 (fr) Conjugués médicament-anticorps
TN2015000396A1 (en) Antibody drug conjugates
WO2014059442A3 (fr) Réactifs à base d&#39;anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
WO2014152157A8 (fr) Procédés et compositions pour la génération et l&#39;utilisation d&#39;anticorps spécifiques à une conformation
PH12020550908A1 (en) Anti-cxcr5 antibodies and compositions and uses thereof
WO2014108484A3 (fr) Thérapie de combinaison avec des anticorps anti-her3
WO2015075269A9 (fr) Anticorps dirigés contre ccr9 et leurs applications
WO2013177055A3 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d&#39;utilisation
WO2014078268A8 (fr) Anticorps anti-hémagglutinine et leurs procédés d&#39;utilisation
WO2015017146A3 (fr) Anticorps à régions de détermination de complémentarité ultralongues
WO2015009715A3 (fr) Imagerie moléculaire et cellulaire utilisant des réponses hémodynamiques modifiées
BR112016010573A8 (pt) composições de fertilizantes
WO2015022077A8 (fr) Nouveaux anticorps du récepteur anti fc-gamma iib et utilisations associées
WO2014159239A3 (fr) Anticorps dirigés contre notch 3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14706737

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14706737

Country of ref document: EP

Kind code of ref document: A2